Cabaret Biotech Ltd. v. Kite Pharma, Inc.
1:19-cv-01732
Overview
Parties
Defendant
Gilead Sciences, Inc. Operating Company
Represented By
2 Attorneys ListedMorris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Morris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Kite Pharma, Inc. Operating Company
Represented By
2 Attorneys ListedMorris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Morris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Plaintiff
Cabaret Biotech Ltd. Operating Company
Represented By
8 Attorneys ListedShaw Keller LLP
1105 North Market Street, 12th Floor, Wilmington, DE 19801
Shaw Keller LLP
1105 North Market Street, 12th Floor, Wilmington, DE 19801
JPMorgan Chase & Co.
JPMorgan Chase & Co., 4041 Ogletown Stanton Road
Court & Judges
Court
District Court, D. Delaware (ded)
Presiding Judge
Global Patent Family Cross-Litigation Radar
CasLoc 360Β° Radar 4 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| πΊπΈ United States | US 7,741,465 Asserted | Asserted Patent | View Official Patent → |
| πΊπΈ United States | US 8,211,422 B2 | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US 2012009384 | US Continuation / Sibling | View Official Patent → |
| π PCT International (WIPO) | WO 1993019163 A1 | PCT World Application | View Official Patent → |
No active co-pending lawsuits found across other jurisdictions for this family. All related sibling filings are currently unlitigated.
Patents Involved
There is a single patent involved in this case.
| Patent Asset | Filing & Issue Date | Expiration & Term Status | External Links |
|---|---|---|---|
|
US7741465
Chimeric receptor genes and cells transformed therewith
|
Filed: 1993-07-02
Issued: 2010-06-22
|
Active (4.5 yrs remaining)
+6542d PTA
Expires: 2031-05-31
|
Patent Enforceability & Injunction Risk Assessment
Active Threat β Patent is within enforceable statutory term. Patentee retains legal standing to seek permanent injunctive relief and exclusion orders.
High PTA (+6542 days) / Cellect Scrutiny β Over 6542 days of PTA awarded. Susceptible to In re Cellect double patenting invalidation if continuation patents in the same family expire earlier.
Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).
Procedural Motions & Interlocutory Orders
Total Motions
33
Dispositive
3
Granted
0
Denied
2
Pending / Review
23
Motions by Category
Key Dispositive Motions & Rulings